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Abstract
Schizophrenia is a severe psychiatric disorder which is worsened substantially by substance abuse/addiction. Substance
abuse affects nearly 50% of individuals with schizophrenia, extends across several drug classes (e.g. nicotine,
cannabinoids, ethanol, psychostimulants) and worsens overall functioning of patients. Prominent theories explaining
schizophrenia and addiction comorbidity include the primary addiction hypothesis (i.e. schizophrenia susceptibility primes
drug reward circuits, increasing drug addiction risk following drug exposure), the two-hit hypothesis (i.e. drug abuse and
other genetic and/or environmental risk factors contribute to schizophrenia development) and the self-medication
hypothesis (i.e. drug use alleviates schizophrenia symptoms). Animal models can be used to evaluate the utility and
validity of these theories. Since this literature was last reviewed by Ng and colleagues in 2013 [Neurosci Biobehav Rev,
37(5)], significant advances have been made to our understanding of schizophrenia and substance abuse comorbidity.
Here we review advances in the field since 2013, focussing on two key questions: 1) Does schizophrenia susceptibility
increase susceptibility to drug addiction (assessing the primary addiction hypothesis), and 2) Do abused drugs exacerbate
or ameliorate schizophrenia symptoms (assessing the two-hit hypothesis and the self-medication hypothesis). We
addressed these questions using data from several schizophrenia preclinical models (e.g. genetic, lesion,
neurodevelopmental, pharmacological) across drug classes (e.g. nicotine, cannabinoids, ethanol, psychostimulants). We
conclude that addiction-like behaviour is present in several preclinical schizophrenia models, and drugs of abuse can
exacerbate but also ameliorate schizophrenia-relevant behaviours. These behavioural changes are associated with altered
receptor system function (e.g. dopaminergic, glutamatergic, GABAergic) critically implicated in schizophrenia and
addiction pathology.
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1. Introduction
Schizophrenia is a severe psychiatric illness affecting approxi-
mately 1% of the population worldwide [1], and is characterised
by a combination of positive symptoms (e.g. delusions, hal-
lucinations, conceptual disorganisation), negative symptoms
(e.g. apathy, social withdrawal, emotional blunting) and cog-
nitive impairment (e.g. impaired executive function, work-
ing memory and attention) [2]. Sex differences are evident
in schizophrenia: males have a higher incidence rate and
an earlier onset of schizophrenia (although females show an
increased incidence of schizophrenia following menopause),
males present with worse negative symptoms and do not re-
spond as well to antipsychotic treatment as females; several of
these differences have been attributed to protective effects of
estrogen in females [3].
Drug abuse and addiction (used interchangeably) is very
common in patients with schizophrenia, occurring up to five
times more frequently than in the general population, and af-
fecting nearly 50% of patients (excluding nicotine dependence,
which affects nearly 90% of patients with schizophrenia) [4, 5].
For example, cannabis abuse occurs in 50% of patients with
schizophrenia, compared to 1% of the general population, nico-
tine abuse occurs in 29% of patients, compared to 13% of
the general population, and alcohol abuse occurs in 43-65%
of patients, compared to 5% of the general population [5].
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Drug abuse causes significant problems for patients by worsen-
ing symptoms, limiting treatment compliance, increasing psy-
chotic relapse and hospitalisation, and increasing suicide risk
[6–11]. Some drugs, such as cannabis and methamphetamine,
increase risk for developing psychosis and schizophrenia; how-
ever, chronic drug abuse can also develop after disease onset,
indicating a complex bidirectional relationship [12]. Several
drug classes are abused in schizophrenia, including cannabis,
psychostimulants (e.g. methamphetamine, cocaine), alcohol
and nicotine [5]. To the authors’ knowledge, sex differences in
the prevalence of substance abuse in patients with schizophre-
nia has not been reported. Despite high rates of substance
abuse in schizophrenia and the significant problems it causes,
the causes of comorbidity are unclear.
1.1 Theories of schizophrenia and drug abuse comor-
bidity
Several theories have been developed to help explain the high
rate of substance abuse in schizophrenia (see [13]). The self-
medication theory suggests that individuals with schizophre-
nia abuse substances to ameliorate symptoms of the disease
[14]; however, this has received limited empirical support
(e.g. [15, 16]). The primary addiction hypothesis purports that
schizophrenia and drug addiction share similar pathophysiol-
ogy in mesocortolimbic circuitry, and thus individuals predis-
posed to schizophrenia also have an elevated propensity for ad-
diction [17]. In the primary addiction hypothesis, drug addic-
tion can occur prior to, but also after developing schizophre-
nia. The two-hit hypothesis claims that genetic or environmen-
tal vulnerabilities (first hit) for schizophrenia interact with ad-
ditional genetic or environmental factor/s (second hit), such
as substance abuse, resulting in the development of psychotic
symptoms and schizophrenia [18]. In the two-hit hypothesis
drug abuse both contributes to and exacerbates schizophrenia
symptoms. Related to this is the shared susceptibility hypoth-
esis, which suggests that poor functioning and the presence
of poverty, victimization and toxic social environments in pa-
tients with schizophrenia accumulate to increase risk for de-
veloping substance abuse [19]. Due to the similarities between
the two-hit hypothesis and the shared susceptibility hypoth-
esis, we will evaluate environmental influences on substance
abuse risk as part of the two-hit hypothesis. Clinical evidence
mostly falls in favour of the primary addiction hypothesis and
the two-hit hypothesis [12]; however, determining cause and
effect can often be difficult in clinical samples due to the eth-
ical implications of administering substances which increase
psychotic symptoms to individuals with schizophrenia. Pre-
clinical rodent models can thus facilitate our understanding of
causative factors for substance abuse and schizophrenia comor-
bidity.
1.2 Rodent models of schizophrenia
Preclinical rodent models of schizophrenia can be used to bet-
ter understand aspects of schizophrenia aetiology, pathophysi-
ology, symptomology and neural function. While no model can
encompass the full spectrum of neurological change within this
uniquely human disorder, models can help us understand how
specific genetic and environmental factors contribute to, and
also interact to bring about the development of schizophrenia.
Furthermore, rodent models allow us to more precisely inves-
tigate different hypotheses for substance abuse comorbidity in
schizophrenia. This review will examine comorbidity between
drug abuse and schizophrenia in the following classes of model:
Genetic models
Genetic models are generated by inserting, knocking down,
deleting or mutating genes relevant to schizophrenia into the
rodent genome [20]. Many genetic risk factors for schizophre-
nia are cumulative and explain a small amount (e.g. 1-2%
of variance) in terms of risk for schizophrenia; thus combi-
nations of risk genes or gene-environment combinations can
improve on these models. Nonetheless, these models often
possess good construct validity for schizophrenia, as causal fac-
tors associated with schizophrenia risk are reproduced in these
models [20].
Neurodevelopmental models
Schizophrenia can be conceptualised as a neurodevelopmental
disorder [21], and manipulations during gestation, birth and
early postnatal development are used to produce irreversible
changes in central nervous system development. Examples of
manipulations include lesions, disruption of neurogenesis dur-
ing critical gestational periods, post-weaning social isolation
and maternal immune activation [20]. Due to the high vol-
ume of data on the neonatal ventral hippocampal lesion (NVHL)
model, we will address this separately to other neurodevelop-
mental models.
Pharmacological models
In patients with schizophrenia, biochemical aberrations of the
dopamine, γ-amino-butyric acid (GABA), glutamate [e.g. ab-
normalities of n-methyl-d-asparate (NMDA) receptors], and
nicotinic receptor systems, as well as functional and struc-
tural changes in the brain are present [22]. Repeated admin-
istration of substances which disrupt these neurotransmitter
systems including phencyclidine (PCP), ketamine, dizocilpine
(MK-801), amphetamine and methamphetamine produces be-
havioural and brain abnormalities which resemble symptoms
of schizophrenia [20]; however, the construct validity (i.e. the
relevance of these pharmacological models to schizophrenia
pathology) of these models is limited.
1.3 Schizophrenia-relevant behaviour in rodents
Schizophrenia-relevant behaviour can be modelled in rodents,
and below we briefly describe behaviours modelling positive,
negative and cognitive symptoms, as well as sensorimotor gat-
ing. For a more detailed review of this topic, see [20, 23, 24].
Positive symptoms of schizophrenia are modelled by tests of
locomotor activity and sensitivity to effects of psychomimetic
drugs on locomotion and stereotyped behaviours. Locomotor
behaviour is considered a proxy measure for psychosis, as both
locomotion and psychosis are elevated by increased dopamine
transmission in the mesolimbic pathway, and both psychosis
and hyperlocomotion in schizophrenia rodent models can be
reduced by antipsychotic treatment [24]. Also, patients with
schizophrenia are sensitive to the psychosis-inducing effects
of psychomimetic drugs (e.g. amphetamines, the NMDA an-
tagonist MK-801) [25], and these drugs can also increase loco-
motor behaviour. However, locomotion is a complex and non-
specific behaviour, and should be interpreted with caution, as
compounds can reduce locomotor activity by mechanisms that
may not be related to antipsychotic efficacy [24].
Negative symptoms of schizophrenia, such as anhedonia, social
withdrawal and loss of motivation are measured through tests
such as sucrose preference (modelling anhedonia), social in-
teraction/social preference (modelling social withdrawal) and
operant progressive ratio testing for food rewards (modelling
loss of motivation) [23, 24]. Sucrose preference measures vol-
untary consumption of a palatable food reinforcer (i.e. sucrose)
as well as water, and a reduction in preference for sucrose over
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water may indicate a limited ability to feel pleasure from a nor-
mally enjoyable activity. The social interaction test measures a
range of behaviours exhibited when two unfamiliar rodents in-
teract freely (e.g. sniffing the conspecific, following, climbing
over/under etc). The social preference test assesses 1) prefer-
ence for investigating an unfamiliar conspecific in a cage com-
pared to an empty cage, and 2) preference for a novel conspe-
cific over a familiar conspecific. While these social tests assess
social behaviours, as well as the preference for socialisation and
social novelty, the degree to which these directly correspond
with social withdrawal in schizophrenia is not clear. Operant
progressive ratio testing examines the motivation to obtain a
food reward. Animals engage in an operant response (e.g. lever
press, nose poke) to receive a food reward (e.g. sugar pellet),
and throughout the session, the response requirements for the
reward are increased, requiring more effort from the animal to
obtain the food reward. This test is considered a measure of
avolition, which can be impaired in schizophrenia [23, 24].
Cognitive impairment in schizophrenia, for example, deficits in
working memory, attention, and executive function, are mod-
elled through an array of rodent cognitive tasks. Most cog-
nitive behavioural tasks reported in this review assess short-
and long-term memory function, using tasks such as fear con-
ditioning (animals learn to associate a tone and/or context with
a footshock), the Morris Water Maze (animals learn to locate
a platform submerged in water over successive days using ei-
ther egocentric or environmental cues), novel object recogni-
tion test (animals investigate a novel object more than a fa-
miliar object) and Y-maze (animals investigate a novel arm in
a Y-shaped maze more than familiar arms). However, there
are more complex tests of cognitive ability which may better
reflect cognitive impairment in schizophrenia. These include
the 5 choice serial reaction time task, where animals in an op-
erant chamber need to identify which of five apertures has been
briefly illuminated, via a nose poke, to receive a food reward;
this assesses attention and inhibitory control [24]. In the set
shifting task, animals learn to dig for a food reward which is
associated with specific cues. When tested, animals need to
respond to relevant cues associated with a food reward (e.g.
digging medium), and ignore cues which do not predict a food
reward (e.g. odour); this assesses rule learning and discrimi-
nation [24]. Rodent touchscreen technology, in which rodents
need to respond to ‘target’ visual pattern stimuli and to with-
hold responses to ‘non-target’ stimuli, permits assessment
of perceptual discrimination, object-place associative learning,
attention, impulsivity, compulsivity, extinction and other do-
mains [26, 27].
A related domain is prepulse inhibition (PPI), a measure of
sensorimotor gating, which is a pre-attentional process to fa-
cilitate stimulus filtering and limit sensory overload [28]. PPI
is the reduction in startle to an auditory or tactile stimulus, by
the prior presentation of a non-startling stimulus [28]. PPI is
measured in rodents assessment of the whole body flinch to
auditory (i.e. tone/white noise) or tactile (i.e. air puff) stim-
uli, and can be disrupted by administration of psychomimetic
drugs [28]. PPI is impaired in patients with schizophrenia, but
PPI deficits are also observed in other disorders e.g. obsessive-
compulsive disorder, Tourette’s syndrome; thus, PPI is not spe-
cific to schizophrenia alone [29].
1.4 Addiction-relevant behaviour in rodents
Here we briefly outline the behavioural assessment of
addiction-relevant behaviour in rodents; however, further
information on these tests can be found in the follow-
ing reviews for conditioned place preference [28–31], be-
havioural/locomotor sensitization [32–34], and drug self-
administration [35, 36].
Conditioned Place Preference (CPP): CPP is an indirect mea-
sure of drug reward, based on context-drug associations. The
CPP apparatus contains two distinct environments (i.e. drug-
paired and vehicle-paired environments), created by a combi-
nation of wall patterns, floor textures and/or scent cues. An-
imals are tested for their baseline preference between these
two compartments, in a pre-test baseline session. Then,
across several days, animals are given vehicle- and drug-
environment pairings (i.e. animals are given a vehicle injection
and confined to the vehicle-paired environment in the morn-
ing, and then in the afternoon or the next day, animals are
given a drug injection and confined to the drug-paired envi-
ronment). This process is repeated several times (e.g. nor-
mally 3-5 vehicle and drug pairings for each animals). At Test,
animals are given free access to both compartments, and if
they spend more time in the drug-paired environment than
the vehicle-paired environment, this indicates the drug was
rewarding. The place preference score is often presented as
the difference between pre- and post-test scores.
Behavioural/Locomotor Sensitization: Behavioural/locomotor
sensitization is defined by the augmented motor-stimulant re-
sponse that occurs with repeated, intermittent exposure to a
drug, and is considered a marker of neural adaptations that can
facilitate future drug taking [32]. Briefly, animals are intermit-
tently administered a drug in a specific context (e.g. an open
field apparatus). Repeated administration of the same drug
dose over successive days/weeks leads to an increase in the
behavioural response to the drug, termed the development of
sensitization. These behaviours can include locomotion and/or
stereotyped behaviours (e.g. sniffing, grooming, head weav-
ing). Expression of sensitization is evident when animals are
given a low-dose drug prime and they exhibit higher levels of
these behaviours than in response to vehicle treatment (i.e. the
behaviours have sensitized).
Intravenous drug self-administration: Rodents can self-
administer drugs of abuse freely within operant chambers, al-
lowing control over the amount and frequency of the drug
administered. Animals can engage in an operant response
(e.g. lever press, nose poke, head movements detected by
infra-red beams), which will provide a drug infusion. Drug
reward can occur in the presence of cues (e.g. light, tone),
and other discriminative stimuli (e.g. scents, wall and floor
textures). An inactive operant response (e.g. lever press on
the ‘inactive’ lever or nose poke in the ‘inactive’ hole) per-
mits assessment of discrimination within the task. Rodents
learn to self-administer abused drugs according to reinforce-
ment schedules e.g. Fixed Ratio (FR) schedules require a fixed
number of operant responses to obtain a drug reward (e.g. FR2
requires 2 lever presses for 1 drug reward), while a Progres-
sive Ratio (PR) schedule requires an increasing number of op-
erant responses to obtain a drug reward. After a period of self-
administration (often 2-3 weeks), animals can be put into ab-
stinence (e.g. kept in home cage with no exposure to operant
chambers) or undergo extinction training, where the drug is
no longer available in the operant chambers, and animals need
to learn to inhibit their responding on the active lever. Extinc-
tion can also be conducted in a different context, mimicking
the change in context which can occur in rehabilitation cen-
tres. Drug-associated cues may also be omitted during extinc-
tion. Relapse-like behaviour can be modelled in reinstatement
and renewal tests, where animals are returned to the operant
chambers and drug-associated cues are presented (i.e. cue-
induced reinstatement), or a low dose drug-prime is adminis-
tered (i.e. drug-primed reinstatement), or the animals experi-
ence a stressor (i.e. stress-induced reinstatement). Renewal
of drug-seeking occurs when an animal is extinguished in a
different context, but is then returned to the original drug-
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taking context, which facilitates drug-seeking. Resumption
of drug-taking can also be modelled after extinction; this is
termed reacquisition.
Intracranial Self-Stimulation: In the intracranial self-
stimulation (ICSS) paradigm, rodents are implanted with in-
tracranial electrodes that target specific brain regions [e.g. me-
dial forebrain bundle of the hypothalamus, ventral tegmental
area (VTA)], and performance of an operant response results
in the delivery of electrical stimulation to that target [37, 38].
ICSS is rewarding as it promotes dopamine release in nucleus
accumbens, it is enhanced by drugs that increase extracellu-
lar dopamine in nucleus accumbens, and it is blocked by drugs
that deplete dopamine or block dopamine receptors [37, 38].
Rodents learn to stimulate the target brain region over several
training days, and ICSS rates levels can modified by parameters
such as pulse frequency, pulse amplitude, stimulus train dura-
tion and schedule of reinforcement [37]. In ICSS paradigms,
ICSS rates are lower at low frequencies (e.g. 56-71 Hz) and in-
crease with higher frequencies (110 Hz+) [37]. The abuse poten-
tial of drugs can be assessed in ICSS: once animals have estab-
lished baseline responding, administration of an abused drug
can shift their baseline ICSS responding e.g. responding at low
frequencies at baseline can be elevated by drug treatment [37].
The facilitation of ICSS responding is indicative of abuse poten-
tial; this may be due to ICSS and drug administration producing
additive effects on mesolimbic dopamine release and transmis-
sion, thus facilitating the operant behaviour which maintains
ICSS [37].
1.5 Methods and literature
During the course of writing this review, we noticed that
interactions between abused substances and schizophrenia
rodent models tended to target two major, yet distinct re-
search questions. One question explored how rodent models
of schizophrenia respond to drugs of abuse in addiction be-
havioural paradigms (e.g. conditioned place preference, loco-
motor sensitization, self-administration). This question eval-
uates the primary addiction hypothesis (i.e. that schizophrenia
and drug addiction share similar pathophysiology in mesocor-
tolimbic circuitry) and investigates if addiction behaviour is ele-
vated in rodent models of schizophrenia, suggesting that risk
for schizophrenia also elevates risk for substance abuse.
The other component of the literature addresses if an-
imal models of schizophrenia are more susceptible to the ef-
fects of abused drugs on schizophrenia-relevant behaviour, includ-
ing whether schizophrenia-like behaviour is exacerbated by
abused drugs in rodent models of the disorder. This compo-
nent addresses the two-hit hypothesis, and evidence in favour
of this hypothesis suggests the development of schizophre-
nia may be facilitated by drug exposure. Alternatively, some
studies also examine the possible therapeutic effects of some
abused drugs in these models, potentially supporting the self-
medication hypothesis.
To provide a structured overview, each component of the re-
view is divided into the model used and the drug investigated.
In 2013, Ng and colleagues reviewed the existing literature on
rodent models of schizophrenia targeting dual diagnosis [39],
andwe refer readers to this review for an in-depth examination
of substance abuse comorbidity in rodentmodels of schizophre-
nia prior to 2013. However, since then a large body of litera-
ture has examined this topic further, providing novel insights
into the behavioural and molecular underpinnings of comorbid
substance abuse in schizophrenia. Here, we present literature
since 2013 on this topic; yet, where relevant (e.g. when limited
information is available on a topic), we refer to older studies
to help inform our conclusions. Literature searches were con-
ducted using PubMed. Our search terms are provided in Table
1.
1.6 Definitions
Here we outline several definitions used within this review.
Developmental periods: Susceptible periods of rodent devel-
opment include the neonatal period [gestational day (G) 1-
18/21] and postnatal period [postnatal day (PND) 1-21], as well
as adolescence (PND 22-60), young adulthood (PND 60-90)
and adulthood (PND 90+). While there is discussion over the
duration of adolescence in rodents [40], we have adopted these
broad definitions, based on a review of the rodent adolescent
literature [40], to provide consistency for the reader.
Drug administration: Drug administration is described as
acute (once-off drug administration, often within 1 hour before
or after experimental manipulation), sub-chronic (3-10 days
drug administration; drugs are often administered 1-2x every
24 hours) or chronic (1-2 administrations per day formore than
10 days).
Schizophrenia-relevant behaviour: Schizophrenia-like be-
haviour can be modelled in rodents using tests to assess posi-
tive and negative symptoms, as well as cognitive impairment
and sensorimotor gating deficits. These are described above in
section 1.3 (reviews: [24, 41, 42]).
Addiction-relevant behaviour: We refer extensively to be-
havioural tests of addiction-relevant behaviour (described
above in section 1.4), including conditioned place prefer-
ence (CPP), behavioural/locomotor sensitization, and drug self-
administration.
2. Addiction-relevant behaviour in rodent
models of schizophrenia
All preclinical studies reviewed in section 2 are summarised in
Tables 2, 3 and 4.
2.1 Genetic models
Addiction-like behaviour in genetic models of schizophrenia
has been examined only for the psychostimulants cocaine and
amphetamine, which increase dopamine release and transmis-
sion in the mesocorticolimbic pathway [43, 44].
Psychostimulants: cocaine and amphetamine
Dopamine metabolism and signalling are critically linked
schizophrenia symptoms, whereby elevated dopamine release
in the mesolimbic pathway is hypothesized to contribute to
positive symptoms, whereas reduced dopamine in the meso-
corticolimbic pathway appears to contribute to negative symp-
toms of the disorder [45, 46]. Altered dopamine signalling
may be linked to dopamine receptor expression, and several
studies indicate D2 receptor expression is elevated in the stria-
tum but reduced in thalamic regions of unmedicated patients
with schizophrenia (review: [47]). Interestingly, mice overex-
pressing dopamine D2 receptors in the paraventricular nucleus
of the hypothalamus (PVT) (i.e. the opposite of what is ob-
served in patients with schizophrenia) show attenuated loco-
motor sensitization to a cocaine challenge, compared to mice
which do not overexpress PVT D2 receptors [48], suggesting
reduced susceptibility to cocaine-induced neural adaptations.
These effects on cocaine sensitization occur in the absence of
altered schizophrenia-relevant behaviours in PVT D2 overex-
pressing mice [48]. The PVT may modulate cocaine sensitiza-
tion via dense projections to critical reward regions such as the
medial prefrontal cortex (mPFC), nucleus accumbens (NAcc),
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Table 1. Search term keywords used in PubMed.
Keyword 1 Boolean operator Keyword 2 Boolean operator Keyword 3
Schizophrenia [Title/Abstract] AND Mouse [Title/Abstract] AND Alcohol [Title/Abstract]
Schizophrenia [Title/Abstract] AND Mouse [Title/Abstract] AND Nicotine [Title/Abstract]
Schizophrenia [Title/Abstract] AND Mouse [Title/Abstract] AND Cannabis [Title/Abstract]
Schizophrenia [Title/Abstract] AND Mouse [Title/Abstract] AND Cocaine [Title/Abstract]
Schizophrenia [Title/Abstract] AND Mouse [Title/Abstract] AND Methamphetamine [Title/Abstract]
Schizophrenia [Title/Abstract] AND Rat [Title/Abstract] AND Cannabis [Title/Abstract]
Schizophrenia [Title/Abstract] AND Rat [Title/Abstract] AND Nicotine [Title/Abstract]
Schizophrenia [Title/Abstract] AND Rat [Title/Abstract] AND Alcohol [Title/Abstract]
Schizophrenia [Title/Abstract] AND Rat [Title/Abstract] AND Cocaine [Title/Abstract]
Schizophrenia [Title/Abstract] AND Rat [Title/Abstract] AND Methamphetamine [Title/Abstract]
Schizophrenia [Title/Abstract] AND Mouse [Title/Abstract] AND Addiction [Title/Abstract]
Schizophrenia [Title/Abstract] AND Mouse [Title/Abstract] AND Substance Abuse [Title/Abstract]
Schizophrenia [Title/Abstract] AND Rat [Title/Abstract] AND Addiction [Title/Abstract]
Schizophrenia [Title/Abstract] AND Rat [Title/Abstract] AND Substance Abuse [Title/Abstract]
Schizophrenia [Title/Abstract] AND Rodent [Title/Abstract] AND Addiction [Title/Abstract]
Schizophrenia [Title/Abstract] AND Rodent [Title/Abstract] AND Drug abuse [Title/Abstract]
amygdala and bed nucleus of the stria terminalis (BNST). The
effects of D2 receptor knockdown/knockout in the PVT have not
yet been examined; however, it would be interesting to observe
whether reduced PVT D2 expression increases cocaine sensi-
tization and other addiction-relevant behaviours, potentially
providing a mechanism for elevated drug abuse susceptibility
in patients with schizophrenia.
The DISC1 gene is a rare genetic risk factor for schizophrenia
that codes for several proteins involved in dopamine signalling
(e.g. cAMP-specific 3’,5’-cyclic phosphodiesterase 4B, ser-
ine/threonine protein kinase Akt and glycogen synthasekinase-
3 (GSK-3) [49, 50]). Several lines of transgenic mice de-
signed to model DISC1 mutations have been created, many of
which exhibit schizophrenia relevant behaviours, including hy-
peractivity, decreased social behaviours, anhedonia in the su-
crose preference test and sensorimotor gating impairment (re-
view: [51]). Recent evidence suggests DISC1 gene alterations
can regulate addiction-relevant behaviour for cocaine in rats
[52]. Disc1 knockdown in the NAcc of rats increases cocaine
self-administration under higher reinforcement schedules [i.e.
FR4-10, but not FR1-2] [52]. Also,DISC1 protein levels are ele-
vated in the NAcc of sham control rats after 12 days of cocaine
self-administration, compared to sham control rats which self-
administer saline [52]. This suggests Disc1 can regulate moti-
vation for cocaine, and upregulation of DISC1 protein may be
a compensatory mechanism following repeated cocaine self-
administration. Importantly, this provides a link between ge-
netic risk for schizophrenia and drug addiction susceptibility,
supporting the primary addiction hypothesis.
Epidermal growth factor (EGF) is involved in cellular prolif-
eration, differentiation, and survival, and a functional sin-
gle nucleotide polymorphism (SNP) in the EGF gene which in-
creases EGF transcription is associated with lower age of onset
of schizophrenia [53, 54]. EGF overexpression in mice facili-
tates acquisition of cocaine behavioural sensitization, such that
cocaine sensitization is much stronger in mice overexpress-
ing EGF, compared to wildtype-like (WT) controls where sen-
sitization did occur but was not very prominent [55]. These
behavioural effects are accompanied by changes in dopamine
metabolites in mice overexpressing EGF: striatal extracellu-
lar levels of tyrosine hydroxylase (TH) are decreased and
catechol-O-methyl-transferase (COMT) increased, whereas
dopa-decarboxylase in the NAcc and frontal cortex are in-
creased, and extracellular dopamine and DOPAC are elevated
in the NAcc [55]. These findings link increased EGF func-
tion with elevated cocaine sensitivity via increased dopamine
metabolism, and also supports the primary addiction hypothe-
sis.
NMDA receptors regulate glutamate signalling which ap-
pears to be dysregulated in schizophrenia, and NMDA dys-
function is observed in post mortem brain tissue of patients
with schizophrenia [56]. Changes to NMDA function can
be modelled using glycine transporter 1 heterozygous knock-
out mice to model NMDA hyperfunction, and serine racemase
knockout to model NMDA hypofunction [57]. Glycine trans-
porter 1 heterozygous knockout in the forebrain (i.e. forebrain
NMDA hyperfunction) enhances cognitive performance in mice
[58, 59], while serine racemase knockout mice (i.e. NMDA hy-
pofunction) exhibit hyperlocomotion, sociability deficits and
greater ventricular volumes [60–62], all of which are relevant
to schizophrenia. In terms of drug abuse potential, both NMDA
hyper- and hypofunction mouse models express place prefer-
ence for cocaine [57]. However, NMDA hypofunction facilitates
extinction of cocaine place preference (i.e. NMDA hypofunction
reduces drug seeking), whereas NMDA hyperfunction enhances
drug-primed reinstatement of cocaine place preference (i.e.
NMDA hyperfunction increases drug seeking) [57]. In addi-
tion, NMDA hypofunction reduces sensitivity to the threshold-
lowering (i.e. rewarding) and the performance-elevating (i.e.
stimulant) effects of cocaine in an intracranial self-stimulation
paradigm [63]. NMDA hypofunction also attenuates cocaine lo-
comotor sensitization [57]; this may be due to blunted cocaine-
induced dopamine and glutamate release in the NAcc [63]. Note
also that a previous study reported that NMDA hypofunction
reduces expression of context-specific sensitization and con-
ditioned hyperactivity for amphetamine, while NMDA hyper-
function facilitates acquisition of amphetamine sensitization
[64]. Together, this suggests that NMDA receptor hypofunc-
tion decreases the rewarding responses of cocaine, and higher
doses of cocaine are required to achieve a hedonic response,
while NMDA hyperfunction increases cocaine reward and ne-
cessitates lower doses of cocaine for a hedonic response. Con-
sidering NMDA receptors appear downregulated in schizophre-
nia, particularly in reward-relevant regions such as the stria-
tum and prefrontal cortex (review: [56]), it seems that individ-
uals with schizophrenia may require higher doses of cocaine to
achieve a rewarding state, increasing the risk of developing se-
vere physiological dependency and withdrawal [63].
Together, these studies demonstrate addiction-like be-
haviour in genetic models of schizophrenia risk. In particu-
lar, genetic models with construct validity for schizophrenia
e.g. Disc1 and EGF transgenic mice, exhibit enhanced addiction-
like behaviour, providing support for the primary addiction hy-
pothesis. Furthermore, EGF transgenic mice exhibit elevated
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Table 2. Addiction-relevant behaviour in genetic and pharmacological rodent models of schizophrenia
Author, date [Refer-
ence]
Model Drug Results - Behaviour (↓decrease,↑increase, ~no effect) Results - Brain (↓decrease,↑increase, ~no effect)
Clark et al 2017 [48] DA D2 receptor over-
expression in the
PVT of mice
Cocaine ↓cocaine sensitization. n/a
Gancarz et al 2016
[52]
Disc1 knockdown in
the Nacc of rats
Cocaine ↑ cocaine self-administration. ↑Nacc DISC1 protein levels after
cocaine self-administration in
shams.
Eda et al 2013 [55] EGF overexpressing
mice
Cocaine ↑cocaine sensitization. in EGF overexpressing mice:↓striatal extracellular tyrosine
hydroxylase, ↑catechol-O-
methyl-transferase.↑ dopa-decarboxylase in Nacc
and FC. ↑Nacc extracellular
dopamine and dopamine
metabolites.
Puhl et al 2015 [60] Glycine transporter
1 HET knockout
mice
Cocaine ~ cocaine CPP and CPP extinction.↑ Cocaine-primed reinstatement. n/a
Puhl et al 2015 [60];
Puhl et al 2019 [63]
Serine racemase
knockout mice
Cocaine ~ cocaine CPP. ↑ cocaine CPP
extinction. ↓ cocaine
sensitization. ↓sensitivity to
cocaine ICSS.
↓cocaine-induced dopamine and
glutamate release in NAcc.
Benneyworth et al
2012 [64]
Glycine transporter
1 HET knockout
mice
Amphetamine ↑amphetamine sensitization.
~expression of amphetamine
sensitization.
n/a
Benneyworth et al
2012 [64]
Serine racemase
knockout mice
Amphetamine ↓Amphetamine sensitization and↓expression of amphetamine
sensitization. ↓Extinction of
amphetamine sensitization.
↑NAcc spine density after
extinction.
Fletcher et al 2018
[110]
Chronic am-
phetamine treat-
ment in rats
Nicotine ~Acquisition and maintenance of
nicotine self-administration.
n/a
Fletcher et al 2018
[110]
Chronic PCP treat-
ment in rats
Nicotine ~Acquisition and maintenance of
nicotine self-administration.
n/a
Abbreviations: CPP, conditioned place preference; DA, dopamine; Disc1; Disrupted in Schizophrenia 1; EGF, epidermal growth factor; FC, frontal cortex; HET;
heterozygous; ICSS, intracranial self-stimulation; NAcc, nucleus accumbens, PCP, phencyclidine.
dopamine metabolism in forebrain regions, and considering
the critical role of dopamine in reward signalling, these models
provide a potential mechanism for elevated addiction propen-
sity in individuals with schizophrenia. Future research will ex-
amine addiction-relevant behaviours in other genetic models
of schizophrenia, to non-psychostimulant drugs.
2.2 Lesion models
The neonatal ventral hippocampal lesion (NVHL) is a widely
used neurodevelopmental animal model, in which an excito-
toxin infusion is made into the ventral hippocampus during
the first postnatal week, a time point roughly comparable to
the third trimester of human development [65]. This lesion
causes neurodevelopmental interruptions hypothesised to be
relevant to schizophrenia susceptibility [66]. The NVHL model
develops behavioural and neurobiological dysfunction relevant
to schizophrenia e.g. social interaction and cognitive impair-
ment, prepulse inhibition deficits, and an enhanced locomotor
response to stress [67, 68].
Psychostimulants: amphetamine and methamphetamine
In a brain stimulation paradigm in young adult rats, reward
thresholds following acute amphetamine are similarly elevated
in NVHL and sham controls, yet this elevation drops off more
rapidly in NVHL rats, indicating increased tolerance for am-
phetamine [69]. In a drug self-administration paradigm,
NVHL rats show higher motivation for methamphetamine self-
administration under a progressive ratio schedule, but no dif-
ferences in responding under a fixed ratio schedule of reinforce-
ment [70].
Psychostimulants: cocaine
Cocaine-induced locomotor activity during sensitization, as
well as locomotion following a cocaine challenge is enhanced in
adult NVHL rats compared to sham controls [71, 72]. However,
when examining gene expression in the caudate-putamen and
mPFC using genome-wide microarrays, there is no overlap in
the direction of gene expression change induced by NVHL and
cocaine sensitization i.e. NVHL mostly downregulates gene ex-
pression in these regions, whereas cocaine sensitizationmostly
upregulates gene expression, compared to sham controls [71].
This analysis included genes associated with neuropsychiatric
conditions (e.g. psychosis, bipolar disorder), such as Estrogen
receptor 2, Glial fibrillary acidic protein, CD 40molecule TNF receptor
Superfamily 5, and several Zinc finger protein genes. There were
a limited number of genes (17% of total genes) impacted on by
NVHL-cocaine interactions, and there was no overlap in the
direction of gene expression change for these interactions [71].
The rarity of convergence of NVHL and cocaine sensitization
effects on individual genes suggests that the NVHL model and
cocaine treatment may interact on the neural network level,
rather than being reducible to one or a few molecular interac-
tions [71].
Cocaine self-administration under fixed ratio responding is
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intact in NVHL rats, yet lesioned rats demonstrate prolonged
extinction and exaggerated cue-induced reinstatement of co-
caine seeking, suggesting impaired prefrontal control over cue-
induced drug-seeking or a general impairment in new action-
outcome learning [73]. Supporting this, working memory
deficits in the radial arm maze in adult NVHL rats predict sub-
sequent cocaine behavioural sensitization, suggesting a link
between cognition and addiction-relevant behaviours in this
model [72]. However, incubation of cocaine craving is not
altered in NVHL rats, suggesting specific addiction-relevant
behavioural domains are altered following NVHL lesions [73].
Collectively, this suggests NVHL rats model several aspects of
increased susceptibility to psychostimulant abuse observed in
individuals with schizophrenia, and suggest changes in gene
expression may interact at a neural network level to facilitate
drug-seeking behaviour.
Nicotine
Nicotine abuse is very common in schizophrenia – up to 90% of
patients smoke cigarettes compared to approximately 26% of
the general population [5]. Animal models have the potential
to unravel this high level of susceptibility to nicotine.
Neonatal ventral hippocampal lesions enhance the reward-
ing effects of nicotine. Adult NVHL rats demonstrate faster
acquisition of nicotine self-administration and higher nicotine
intake during self-administration ([74] but see also [72, 75]),
modelling the higher levels of smoking observed in schizophre-
nia patients. Adult NVHL rats are also resistant to reducing
nicotine use, exhibiting slower extinction of nicotine seeking
and elevated drug-primed reinstatement compared to sham
controls [72, 74, 75].
Increased susceptibility to nicotine may be age-dependent,
occurring only in adult NVHL but not adolescent NVHL rats.
Nicotine sensitization in adolescence is similar between NVHL
and sham controls [74]. Furthermore, prior nicotine sensitiza-
tion does not affect acquisition or extinction of nicotine self-
administration, suggesting adolescent nicotine treatment does
not facilitate later nicotine consumption [74]. While nicotine
sensitization increases responding for a high nicotine dose (30
µg/infusion, dose-response study), this is unaffected by NVHL
[74]. Together, this data suggests that schizophrenia pathol-
ogy may precipitate vulnerability to nicotine addiction later in
life, but early nicotine exposure does not modulate this rela-
tionship.
Interestingly, when both ethanol and nicotine are available
in a self-administration paradigm, NVHL rats display greater
consumption of both ethanol and nicotine compared to sham
controls [75]. During extinction, when both ethanol and nico-
tine are unavailable, NVHL rats exhibit elevated responding
for these two drugs, compared to sham controls [75]. Drug-
primed reinstatement of nicotine-seeking is greater in NVHL
rats compared to sham controls, but this is unaffected by
ethanol availability [75]. These findings indicate vulnerability
of NVHL rats to both substances when they are concurrently
available.
Ethanol
Alcohol abuse is also observed at higher rates in schizophre-
nia (43-65% of patients experience alcohol dependence) than
in the general population (approximately 5%) [5]. Adoles-
cent alcohol use is associated with elevated use in adulthood
in healthy controls [76]; however, susceptibility to the effects
of adolescent alcohol use on brain reward dysfunction is un-
known in schizophrenia. NVHL rats can be used to model this
relationship. Indeed, NVHL rats are susceptible to adolescent
ethanol exposure: NVHL rats given chronic voluntary ethanol
access during adolescence demonstrate higher rates of ethanol
consumption in two-bottle free choice in adulthood compared
to sham controls given voluntary ethanol access in adoles-
cence. NVHL rats with adolescent ethanol access also show
escalation of ethanol self-administration, delayed extinction
of ethanol-seeking and higher rates of drinking during reac-
quisition compared to sham controls with adolescent ethanol
access [77]. These effects occur despite similar levels of ado-
lescent ethanol intake between NVHL and sham rats, and im-
portantly, addiction-like phenotypes (e.g. escalation of intake,
resistance to extinction) are only present in NVHL rats which
experience adolescent exposure to ethanol [77]. These findings
indicate that NVHL lesions do not have an impact on the im-
mediate effect of ethanol in adolescence but increase later sus-
ceptibility for addictive-like behaviour, supporting a two-hit
model of addiction susceptibility i.e. early drug exposure and
schizophrenia/addiction susceptibility increases risk for addic-
tion in later life.
For a natural reinforcer (e.g. sucrose), in a self-
administration paradigm, NVHL rats show intact extinction
learning, and reacquisition of responding is similar to controls
[77]. NVHL rats do however exhibit impaired acquisition and
maintenance of autoshaping for a food reinforcer following
latent inhibition, and impaired extinction of autoshaping be-
haviour [78], suggesting select cognitive deficits in this model.
Interestingly, these cognitive deficits may contribute to the
ethanol addiction-relevant phenotype of NVHL rats, as the de-
gree of latent inhibition in NVHL rats predicts future ethanol
drinking [78], suggesting a link between cognitive impairment
and elevated ethanol consumption in this model.
Cannabinoids: CB1 receptor agonists WIN 55,212-2 and ∆9-
tetrahydrocannabinnol
CB1 cannabinoid receptor agonists are of particular relevance to
schizophrenia because CB1 receptors mediate the psychoactive
and rewarding properties of cannabis [79], and there is strong
evidence linking adolescent cannabis use with increased risk
for schizophrenia, particularly in individuals with genetic pre-
disposition for the disorder (reviews: [80, 81]). In addition,
cannabis abuse is 3-4x higher in patients with schizophrenia
than in healthy populations [5]. Assessing addiction-relevant
behaviours for CB1 receptor agonists in schizophrenia rodent
models can provide insights into why cannabis use is so com-
mon in schizophrenia. It should be noted that in many rodent
studies, CB1 receptor agonists fail to produce rewarding and
reinforcing effects [82–84], or only do so under specific exper-
imental conditions, which may be due to concurrently occur-
ring aversive properties of these drugs mediated by effects of
cannabinoids on other receptors (e.g. in mice, κ-opioid recep-
tors mediate aversive effects of THC); see discussion in [84].
NVHL rats exhibit an age-specific susceptibility to the CB1
receptor agonist WIN 55,212-2 (WIN) [85]. While acute WIN
treatment has no effect on locomotion in adolescence in NVHL
rats, WIN increases locomotor activity in young adult NVHL
rats, compared to sham controls [85]. In addition, young
adult but not adolescent NVHL rats exhibit a greater aversion
to WIN in a conditioned place preference paradigm compared
to controls, yet the opposite effect occurs for CB1 receptor ag-
onist ∆9-tetrahydrocannabinnol (THC), where sham controls
demonstrate an aversion for THC, which is not present in NVHL
rats [85]. These findings are mirrored in a brain stimulation
reward paradigm, where THC produces a weak attenuation of
reward in sham controls, but not NVHL rats, and WIN has the
opposite effect, attenuating reward in NVHL rats but enhancing
it in controls [69]. The different effects of THC and WIN may
be due to different pharmacokinetics between the two drugs
(e.g. WIN has a higher CB1 receptor affinity than THC [86]),
and/or cannabinoid receptor expression in reward regions [(e.g.
striatum, VTA] in NVHL rats, but this has not been assessed.
Nonetheless, together this suggests NVHL alters the sensitivity
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of the endocannabinoid system to reward, in a manner specific
to the reinforcer used (e.g. NVHL increases sensitivity to WIN,
but decreases sensitivity to THC).
2.3 Non-lesion neurodevelopmental models
Non-lesion neurodevelopmental models of schizophrenia in-
duce a pre- or post-natal insult via maternal cytokine eleva-
tion [e.g. administration of mitotoxin methylazoxymethanol
acetate (MAM), lipopolysaccharide (LPS), polyinosinic-citidilic
acid (Poly I:C) or quinpirole], prenatal stress or rearing envi-
ronment manipulations during the post-natal period. Pups
tested in adolescence and/or adulthood show altered addiction-
relevant behaviour to several drugs of abuse. It should be noted
that the timing of maternal infection and the infectious agent
chosen can influence behavioural and neurological outcomes,
and the current lack of consistency across research groups in
the implementation of maternal infection may cause differ-
ences in the outcomes [87, 88].
Psychostimulants: amphetamine
Altered dopaminergic function is observed in the Poly I:Cmodel,
where prenatal Poly I:C treatment in mice enhances locomo-
tor sensitization and stereotyped behaviour to repeated am-
phetamine administration, compared to control offspring [89].
Also, amphetamine CPP is greater in Poly I:C offspring com-
pared to control offspring, suggesting heightened reward for
amphetamine [89]. Similarly, prenatally MAM-treated rats
show a greater stereotyped behavioural response to an am-
phetamine challenge dose than controls, suggesting greater
expression of amphetamine sensitization following prenatal
MAM treatment [90]. This suggests maternal infection can
increase sensitivity to the rewarding and locomotor stimulat-
ing effects of psychostimulants, and may suggest heightened
dopaminergic system function.
Psychostimulants: cocaine
Mice prenatally exposed to Poly I:C exhibit enhanced cocaine
reward in CPP, indicating stronger cocaine context-reward as-
sociations [91]. Despite elevated cocaine context-reward asso-
ciations, Poly I:C treated mice exhibit reduced cocaine-induced
locomotor activity, which may indicate lower dopamine trans-
porter or dopamine receptor availability in brain regions such
as the VTA or striatum [91]. Prenatal Poly I:C treatment in rats
also enhances cross-sensitization to cocaine after behavioural
sensitization to amphetamine, suggesting elevated susceptibil-
ity to other stimulant drugs following repeated amphetamine
administration [89]. Interestingly, Poly I:C mice do not exhibit
place preference for a natural reward, sucrose, where control
mice do, yet learning about an aversive stimulus (i.e. fear con-
ditioning) is intact, suggesting impaired processing of appet-
itive reward in this model [91]. Collectively, this suggests in-
creased susceptibility to stimulant reward in Poly I:C treated
animals, but disrupted reward processing for natural rewards,
which may reflect distinct neuronal changes (e.g. within the
PFC-NAcc glutamate pathway and/or downstream in medium
spiny neurons) that occur following exposure to drug vs natural
rewards [92].
In rats which experience early life adversity [i.e. limited
bedding and nesting (LBN) during PND 2-9], cocaine sensiti-
zation is unaffected. However, acute cocaine administration
increases c-Fos expression in reward regions such as the NAcc
core, central amygdala and lateral habenula of LBN rats, com-
pared to controls [93]. c-Fos expression in orexin/hypocretin
neurons following acute cocaine in LBN rats is decreased in the
lateral, dorsomedial and perifornical regions of hypothalamus,
suggesting reorganization of drug reward and stress circuitry
following early life stress [93].
Despite elevated neuronal activity in reward regions fol-
lowing acute cocaine [93], cocaine self-administration be-
haviours are mostly unaltered in neurodevelopmental models
of schizophrenia. While LBN rats initially acquire cocaine self-
administration faster than controls, LBN rats self-administer
similar amounts of cocaine as controls after 10 days of train-
ing, and exhibit similar sensitivity to different cocaine doses
[93]. Cocaine extinction and reinstatement of cocaine-seeking
are also unaltered in LBN rats [93]. Interestingly, the hedonic
set point for cocaine is reduced, such that LBN rats prefer to
self-administer lower doses of cocaine under low effort con-
ditions but demonstrated similar levels of motivation to self-
administer cocaine under higher effort conditions [93]. This
suggests either a degree of cocaine anhedonia in LBN rats or
that LBN rats reach cocaine satiety faster than controls, and
suggests limited bedding and nesting does not increase cocaine
addiction-like behaviours.
In the MAM neurodevelopmental model of maternal infec-
tion, there are no differences in cocaine self-administration
under fixed and progressive schedules of reinforcement, nor
in extinction or drug-induced reinstatement for cocaine [94].
Similarly, offspring of dams treated with LPS show unaltered
cocaine self-administration, dose-response curves and extinc-
tion, despite workingmemory and sensorimotor gating impair-
ment in this model [95]. Acute locomotor activity in response
to various doses of cocaine is unaltered in MAM rats, compared
to controls [94].
Together, this demonstrates sensitivity to cocaine
addiction-relevant behaviours is highly dependent on the
neurodevelopmental model used, for while Poly I:C treatment
seems to increase cocaine reward and cross-sensitization,
other neurodevelopmental models e.g. LBN, MAM, prenatal
LPS, do not exhibit a cocaine addiction-like phenotype, or
demonstrate a phenotype which suggests reduced susceptibil-
ity to cocaine (e.g. LBN show cocaine anhedonia).
Psychostimulants: methamphetamine
There are limited effects of prenatal MAM treatment
on methamphetamine responses in offspring. Prenatal
MAM treatment does not affect methamphetamine self-
administration under an FR1 schedule of reinforcement, or cue-
induced reinstatement after abstinence, in male or female rats
[96]. Dose-response, schedules of reinforcement and extinc-
tion behaviour for methamphetamine have not yet been ex-
amined in MAM rats. However, MAM offspring are less sus-
ceptible to the suppressing effects of low dose ketamine on
methamphetamine self-administration than control rats, and
the authors suggest this may be due to impaired PFC gluta-
matergic signalling inMAM rats [97]. Further research into the
effects of neurodevelopmental insults on addiction behaviour
for methamphetamine are warranted.
Nicotine
Developmental stress appears to increase sensitivity to nico-
tine. Adult rats which experienced prenatal stress exhibit
greater nicotine reward in CPP than offspring of non-stressed
rats [98]. Also, rats reared in isolation during adolescence
show behavioural sensitization to repeated nicotine adminis-
tration during adolescence, where rats reared in an enriched
environment do not [99]. LPS treatment during gestation fa-
cilitates intravenous nicotine self-administration at higher re-
inforcement schedules (i.e. FR5, not FR1/FR2), but has no sub-
sequent effects on dose-response responding or motivation for
nicotine under a progressive ratio [100]. Similarly, in the MAM
rat model of schizophrenia, Weeks and colleagues found no
differences between MAM rats and controls in nicotine self-
administration [101]. This was observed across a range of doses
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Table 3. Addiction-relevant behaviour in neonatal ventral hippocampal lesion rat models of schizophrenia
Author, date [Refer-
ence]
Model Drug Results - Behaviour (↓decrease,↑increase, ~no effect) Results - Brain (↓decrease,↑increase, ~no effect)
Gallo et al 2014 [69] NVHL rat Amphetamine ↑tolerance for amphetamine in
ICSS.
n/a
Brady et al 2008 [70] NVHL rat Methamphetamine ~ methamphetamine
self-administration (dose range).
n/a
Chambers et al 2013
[71]; Rao et al 2016 [72]
NVHL rat Cocaine ↑Cocaine sensitization and↑expression of cocaine
sensitization.
~ gene expression change in stria-
tum and mPFC after cocaine sensi-
tization in NVHL.
Karlsson et al 2013 [73] NVHL rat Cocaine ~Cocaine self-administration.↓Extinction and ↑cue-induced
reinstatement for cocaine.
~Incubation of cocaine craving
n/a
Rao et al 2016 [72];
Berg et al 2014 [74];
Sentir et al 2018 [75]
NVHL rat Nicotine ~Nicotine sensitization. ~Nicotine
sensitization on acquisition or
extinction of nicotine
self-administration. Nicotine
sensitization in NVHL ↑’s nicotine
self-administration, ↓extinction
and ↑nicotine-primed
reinstatement.
n/a
Sentir et al 2018 [75] NVHL rat Nicotine ↑Ethanol and nicotine
self-administration (when
available together). ↓Extinction of
nicotine and ethanol.↑Nicotine-primed reinstatement.
n/a
Jeanblanc et al 2015
[77]
NVHL rat Ethanol Following adolescent ethanol
exposure, NVHL show ↑ethanol
free consumption, ↑escalation of
ethanol self-administration,↓extinction and ↑reacquisition of
ethanol.
n/a
Jeanblanc et al 2015
[77]; Khokhar et al
2018 [78]
NVHL rat Sucrose ~Extinction and ~reacquisition for
sucrose. ↓acquisition and
maintenance of autoshaping
following latent inhibition.↓Impaired extinction of
autoshaping behaviour for sucrose.
n/a
Gallo et al 2014 [69];
Gallo et al 2014 [85]
NVHL rat WIN In NVHL, ↑WIN-induced
locomotion in young adulthood.↓WIN CPP in young adult NVHL.
WIN ↓ICSS reward in NVHL.
n/a
Gallo et al 2014 [69];
Gallo et al 2014 [85]
NVHL rat THC ↓THC CPA in early adult NVHL.
~THC CPP in adolescent NVHL.
~THC ICSS in NVHL.
n/a
Abbreviations: CPA, conditioned place aversion; CPP, conditioned place preference; ICSS, intracranial self-stimulation; mPFC, medial prefrontal cortex; NVHL,
neonatal ventral hippocampal lesion; WIN, WIN 55,212-2.
and schedules of reinforcement, in both standard 1-hr self-
administration sessions and 23-hr extended access sessions,
and this was not different between the sexes [101]. Interest-
ingly, MAM animals responded less for sucrose or reinforcing
visual stimuli alone or when paired with nicotine, suggesting
potential deficits in reinforcement learning in this model [101].
Thus, it seems that developmental stress can increase suscep-
tibility to nicotine addiction-like behaviour in adulthood, but
this is not the case following maternal infection.
NAcc dopamine D2 receptor mRNA expression levels are el-
evated in adult rats which are prenatally stressed [98], while
chronic postnatal quinpirole treatment, which increases D2 re-
ceptor sensitivity, enhances sensitization during adolescence
to nicotine [99]. This suggests elevated D2 receptor function
may underlie effects of prenatal stress on nicotine reward. Im-
portantly, elevations in D2 mRNA expression induced by pre-
natal stress are reduced by sub-chronic (8 day) nicotine treat-
ment during adulthood [98], suggesting this effect may be
reversible and potentially supporting the self-medication hy-
pothesis.
Chronic nicotine treatment also increases glial cell line-
derived neurotrophic factor (GDNF) levels in the NAcc, and
neonatal quinpirole reduces elevated GDNF levels induced by
nicotine in isolation-reared rats [99]. Considering GDNF is
critical for dopaminergic plasticity in reward-relevant brain re-
gions [102], it is possible that elevated sensitivity to nicotine
in neurodevelopmental rodent models of schizophrenia may be
due to altered dopamine receptor function in reward regions
(e.g. NAcc).
Ethanol
Recently, Ruda-Kucerova and colleagues found no differences
in ethanol consumption using a voluntary consumption pro-
cedure or resumption of ethanol drinking after abstinence in
male or female rats exposed to MAM prenatally [96]. How-
ever, other preclinical studies (pre-2013) have shown that early
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life stress (e.g. social isolation stress, chronic variable stress)
can increase adult ethanol intake (e.g. [103–107], see also re-
views: [108, 109]). Elevated ethanol intake in other neurode-
velopmental models may be linked to molecular changes such
as decreased firing of dopaminergic VTA neurons in an LPS
model [103], and may be related to altered anxiety-like states,
as ethanol consumption in two-bottle free choice can be re-
duced by administration of anxiolytic adrenergic drugs [105].
Together, this suggests a critical role of the schizophrenia-
relevant model on ethanol intake and ethanol-seeking be-
haviour.
2.4 Pharmacological models
Nicotine
Only one study has examined how pharmacological models
of schizophrenia respond to nicotine addiction-relevant be-
haviours. In models of reduced dopamine sensitivity (i.e.
chronic adult amphetamine treatment) or glutamatergic dys-
function (i.e. chronic adult PCP treatment), acquisition and
maintenance of intravenous nicotine self-administration is un-
affected [110]. It should be noted that prior research demon-
strates reduced brain stimulation reward and sucrose consump-
tion in chronic PCP models, suggesting altered addiction-like
phenotypes in this model [111, 112]. Considering this, further
investigation into how pharmacological schizophrenia models
respond in addiction behavioural paradigms is warranted.
2.5 Interim Summary
From the literature reviewed, it is clear that susceptibility to
addiction-like behaviour depends on the model assessed and
also the drug tested. The NVHL rat in particular exhibits el-
evated addiction-like behaviours to many abused drugs, in-
cluding psychostimulants, nicotine, ethanol and cannabinoids.
Some genetic models (e.g. Disc1 knockdown and EGF trans-
genic) also exhibit addiction-relevant behaviour for psychos-
timulants; however, other drugs of abuse have not been as-
sessed in these models, and this is an area of critical further
study. Similarly, pharmacological models of schizophrenia re-
main practically unexplored in their addiction-like behaviour.
In non-lesion neurodevelopmental models, addiction-like phe-
notypes appear dependent on the drug tested, with several
models showing elevated addiction-like behaviour for nicotine,
but not methamphetamine or ethanol, and only one model ex-
hibiting addiction-like behaviour for cocaine. Cannabinoids
have not been assessed in non-lesion neurodevelopmental
models. Addiction-like behaviours for opioids have not yet
been assessed in any rodent model of schizophrenia, and this is
an interesting area of future research, as recent research sug-
gests patients with schizophrenia abuse opioids less than the
general population [113]. The reasons for why some models
show addiction-like phenotypes and some do not is currently
unclear; however, there appear links to altered dopaminergic
signalling in models which do show addiction-like phenotypes
e.g. EGF overexpressing mice, prenatally stressed rats. The
mechanisms driving the presence of addiction-like phenotypes
in different models is an area of critical further research.
The type of research reviewed above is critical for under-
standing which genetic and environmental schizophrenia risk
factors influence addiction susceptibility. This is particularly
important for genetic risk factors e.g. DISC1, EGF, as this could
facilitate future genetic counselling for patients carrying these
mutations about their elevated risk for addiction, providing
a personalised medicine approach. Furthermore, these stud-
ies have started to shed light on molecular changes linked
to elevated addiction propensity in schizophrenia models e.g.
changes in dopamine metabolism and D2 receptor function,
increasing our understanding of potential mechanisms of co-
morbidity between these disorders. So far, the examination of
mechanisms underlying addiction propensity in schizophrenia
models has been limited, and has focused mostly on dopamin-
ergic function; future research can examine other changes to
other addiction-relevant neurotransmitter systems (e.g. glu-
tamatergic, serotonergic) as well as plastic and epigenetic
changes in mesocorticolimbic regions.
3. Susceptibility of schizophrenia rodent
models to effects of drugs on schizophrenia-
relevant behaviour and brain function
All preclinical studies reviewed in section 3 are summarised in
Tables 5 - 9.
3.1 Genetic models
Psychostimulants – amphetamine, methamphetamine, dopamine
agonists
Brain derived neurotropic factor (BDNF) is critical for hip-
pocampal synaptic plasticity and the regulation of learning
and memory [114, 115]. BDNF protein is reduced in first
episode, drug naïve patients with schizophrenia [116, 117] and
is increased after antipsychotic treatment [118]. BDNF mRNA
expression is reduced in post-mortem PFC tissue from pa-
tients with schizophrenia [119], and BDNF is implicated in neu-
ral responses to psychostimulants [120]. Heterozygous BDNF
mice (i.e. BDNF HET mice) exhibit prepulse inhibition deficits
at baseline [121], similar to that observed in patients with
schizophrenia [122].
Adult male BDNF HET mice are more sensitive to the dis-
ruptive effects of acute amphetamine on PPI compared to WT
mice, but this sensitivity is not observed in female BDNF HET
mice [121]. However, adult male or female BDNF HET mice do
not exhibit differential sensitivity to the disruptive effects of
acute apomorphine, a dopamine D1 and D2 partial agonist on
PPI, suggesting drug-specific effects on PPI disruption, which
may be linked to the pharmacodynamics of each dopaminer-
gic drug (e.g. amphetamine reverses monoamine transporters,
while apomorphine is a dopamine D1 and D2 partial agonist)
[121].
In BDNF HET mice (sexes collapsed), chronic adolescent
methamphetamine administration reduces cross-sensitization
of locomotion to acute amphetamine, suggesting an attenua-
tion of behaviours relevant to psychosis in methamphetamine-
treated BDNF HET mice [123]. However, chronic adoles-
cent methamphetamine administration does not alter other
schizophrenia-relevant behaviours, such as social preference,
social novelty, baseline prepulse inhibition or short-term
memory in the Y-maze in BDNF HET males or females, com-
pared to WT littermate controls [121, 124]. Methamphetamine-
induced locomotion during the adolescent administration pe-
riod is also similar between BDNF HET and WT mice, in both
sexes [121]. This suggests that chronic adolescent metham-
phetamine in BDNFHETmice affects cross-sensitization to am-
phetamine, but has no effect on some schizophrenia-relevant
social and cognitive behaviours.
In a mouse model of DISC1 with the L100P amino acid sub-
stitution in exon 2 in Disc1, acute methamphetamine-induced
locomotion is not different to WT controls [125]. The ef-
fect of methamphetamine on other schizophrenia-relevant be-
haviours in this model has not been assessed. Considering
other Disc1 models (e.g. Disc1 knockdown, Disc1 dominant neg-
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ative mutation, discussed below) exhibit greater susceptibility
to addiction-like behaviour for cocaine and the cognitive im-
pairing effects of THC, further work on this mouse model is
warranted.
Together, these data suggest a limited effect of psychostim-
ulants on schizophrenia-relevant behaviour in genetic mod-
els; however, PPI is disrupted by amphetamine and cross-
sensitization to methamphetamine is reduced in BDNF HET
mice.
Nicotine
A schizophrenia genetic susceptibility model, the Snap-25 KO
mouse, has a heterozygous deletion of the presynaptic pro-
tein SNAP-25, which is a critical component of the SNARE
protein-protein complex responsible for action-potential trig-
gered release of neurotransmitters [126]. Snap-25 KO mice do
not exhibit schizophrenia-relevant behaviours in adolescence
at baseline e.g. locomotor hyperactivity, social withdrawal;
however, there is a gene * in utero interaction, whereby locomo-
tor hyperactivity and social withdrawal in adolescence are evi-
dent following prenatal nicotine exposure in Snap-25 KO mice,
but not WT controls [126]. Prenatal nicotine treatment in Snap-
25 KO mice also impairs striatal D2 receptor dependent long-
term depression (LTD) and reduces striatal D2 receptor affin-
ity, but leaves striatal CB1 receptor regulated plasticity intact,
compared to Snap-25 KO mice without prenatal nicotine expo-
sure [126]. This suggests that intact expression and function
of Snap-25 may be protective against the effects of prenatal
nicotine on schizophrenia-like behaviour, as well as striatal
D2 receptor expression and function.
SNPs in the human CHRNA5 gene, which encodes the α5
nicotinic acetylcholine (nACh) receptor subunit, increases risk
for both smoking and schizophrenia [127]. Mice which ex-
press a human α5 SNP (i.e. α5-SNP-expressing mice) show
impaired social behaviour and sensorimotor gating, as well
as lower activity of vasoactive intestinal polypeptide (VIP)
interneurons, which results in increased somatostatin in-
terneuron inhibitory drive over layer II/III pyramidal neurons
[128]. Importantly, the decreased activity observed in α5-SNP-
expressing mice resembles the hypofrontality observed in pa-
tients with schizophrenia and addiction [128]. Chronic nico-
tine administration reverses this hypofrontality, supporting
the self-medication hypothesis when alterations to nACh sub-
unit α5 are present [128].
G72 is a gene from schizophrenia-associated genetic region
SCZD7 on chromosome 13q32-q33, and elevated G72 transcript
levels are observed in forebrain structures in post-mortem tis-
sue of patients with schizophrenia [129]. In transgenic mice
overexpressing G72, chronic adult nicotine administration re-
verses impairments in social memory, working memory and
PPI, compared to vehicle G72 transgenic mice [130]. Chronic
nicotine also reverses the upregulation of oxytocin receptor
binding in the central amygdala observed in vehicle treated G72
transgenic mice, which may relate to improvements in social
memory in nicotine-treated G72 transgenic mice [131]. The G72
mutation is also protective against operant associative mem-
ory deficits caused by chronic nicotine, but long-term spatial
learning in the Morris Water Maze is worsened by chronic nico-
tine treatment in G72 mice [130], suggesting domain-specific
effects of chronic nicotine in this model.
Reelin is a large extracellular matrix protein critically in-
volved in brain development and neural plasticity. Reelin
deficits have been observed in schizophrenia [132], and het-
erozygous reeler mice exhibit hyperlocomotion, PPI and cog-
nitive deficits, and perseverative behaviour [133–135], as well
as a loss of Purkinje cells of the cerebellum, which is also
observed in patients with schizophrenia [136, 137]. In ado-
lescent heterozygous reeler mice, subchronic (6 day) nicotine
free choice drinking ameliorates hyperlocomotion, persevera-
tive behaviour and cognitive impairment [138, 139]. Further-
more, in heterozygous reelermice, subchronic nicotine restores
mRNA levels of reelin and GAD67 in the cortex, hippocampus,
striatum and cerebellum to WT-like levels [138, 139]. Together,
this suggests protective effects of subchronic nicotine in the
heterozygous reeler mouse.
Neuregulin 1 is a well-established risk gene for schizophre-
nia, involved in processes such as axon guidance, synapse
formation and synaptic plasticity, as well as excitatory glu-
tamatergic and inhibitory GABAergic transmission [140, 141].
Alternative splicing leads to >30 NRG1 isoforms, and several
mouse models have been developed to study altered Nrg1 func-
tion with reference to schizophrenia. Type III Neuregulin 1 het-
erozygous knockout (Type III Nrg1 HET) mice exhibit social in-
teraction impairment and PPI deficits at baseline. Type III Nrg1
HET mice are also less sensitive to the effects of acute nico-
tine on theta-burst stimulation elicited long-term potentiation
(LTP) in cortical-basolateral amygdala (BLA) synapses, such
that in WT mice, nicotine reduces the threshold for the activa-
tion of LTP in cortical-BLA synapses, but this effect is absent in
Type III Nrg1 mutant mice [142]. This effect in Type III Nrg1 HET
animals is dependent on α7 nicotinic receptors [142]. Inter-
estingly, chronic (6 weeks) nicotine consumption in drinking
water improves PPI in Type III Nrg1 transgenic mice [143]. Con-
sidering that the ameliorative effects of nicotine on PPI deficits
involve α7 nicotinic receptors [144], and type III NRG1 backsig-
nalling regulatesα7 nicotinic receptor surface expression [145],
it is possible that chronic nicotine treatment in Type III Nrg1mu-
tant mice may restore α7 nicotinic receptor surface expression
in the cortex and BLA to WT levels.
Together, these studies indicate that sensitivity to the ef-
fects of nicotine on schizophrenia-relevant behaviour and
brain function depends on the model used, with most models
showing protective or ameliorative effects of nicotine (e.g. G72
transgenic, heterozygous reeler, Type III Nrg1 transgenic mice),
but some models showing development of schizophrenia-
relevant behaviours only following nicotine administration
(e.g. Snap-25 KO mice). Considering several models show
ameliorative effects of nicotine, this provides support for
the self-medication hypothesis, whereby nicotine improves
schizophrenia-relevant behaviour and brain function, which
may help explain high usage rates in patients. Nicotine ad-
ministration is accompanied by a range of neural changes, in-
cluding reduced striatal LTD, increased oxytocin receptor bind-
ing in the central amygdala, increased reelin and GAD67 mRNA
expression in the hippocampus, striatum, cortex and cerebel-
lum, and a reduced threshold for LTP activation in cortical-BLA
synapses, The timing of nicotine administration (e.g. neonatal
vs adolescence vs adulthood) may impact on potential ameliora-
tive effects of nicotine, but this has not yet been investigated.
NMDA antagonists
A novel Type III Nrg1 overexpression mouse (i.e. Nrg1 III
tg), which models the elevated Type III NRG1 mRNA de-
tected in postmortem dorsolateral PFC tissue of patients with
schizophrenia [146], exhibits sex-specific cognitive, social and
prepulse inhibition impairment, but no changes to locomotor
activity in either sex [147]. However, acute hyperlocomotor ac-
tivity in response to the NMDA antagonist MK-801 is blunted
in adult female Nrg1 III tg mice [147]. Interestingly, this effect
is not observed in adult male Nrg1 III tg mice, where hyperloco-
motion following MK-801 is similar to WT mice [148]. This
may suggest a reduced number of available NMDA receptors
in Nrg1 III tg female mice, in alignment with the NMDA recep-
tor hypofunction theory of schizophrenia [56]. However, in
BDNF HET mice, acute MK-801 does not differentially affect
prepulse inhibition in male or female BDNF HETs compared to
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WT mice [121], indicating model-specific effects of MK-801 on
schizophrenia-relevant behaviour.
Cannabinoids: Cannabidiol
Spontaneously hypertensive rats (SHR) are a model of
schizophrenia, exhibiting behaviours including hyperlocomo-
tion, sensorimotor gating deficits, associative memory im-
pairment and reduced social behaviour [149]. Cannabidiol
(CBD) is a non-intoxicating cannabis plant compound which
is a weak CB1 receptor negative allosteric modulator [150],
and is being investigated as a potential anti-psychotic [151].
In SHR, acute CBD treatment does not reverse hyperlocomo-
tion and social withdrawal [152]. However, chronic low dose
(i.e. 0.5 – 5 mg/kg) CBD treatment during adolescence dose-
dependently reverses locomotor hyperactivity, sensorimotor
gating deficits and fear-associated cognitive impairment in
SHR [153]. Chronic adolescent CBD treatment also increases the
ratio of 5-HIAA/serotonin tissue levels in the PFC in adulthood
in both SHR and controls, but CBD has no effect on serotonin
levels in the dorsal striatum or BDNF levels in the PFC or dorsal
striatum [153], suggesting that CBD ameliorates schizophrenia-
relevant behaviours in SHR by a different mechanism (e.g. in-
creasing anandamide levels [154]).
Similarly, in a different Neuregulin 1 mouse model of
schizophrenia (i.e. the Neuregulin 1 transmembrane domain het-
erozygous mouse, Nrg1 TM HET), which exhibits hyperlocomo-
tion, impaired social behaviour and PPI deficits at baseline
[155, 156], acute treatment with higher doses of CBD (i.e. 50 -
100 mg/kg) reverses PPI deficits, compared to vehicle treated
Nrg1 mutants [157]. Also, chronic treatment in this dose range
increases social behaviour and increases GABA-A receptor bind-
ing in the granular retrosplenial cortex in adult Nrg1 TM HET
mice [157]. However, chronic CBD does not reverse locomotor
hyperactivity, sensorimotor gating deficits or reduced 5-HT2A
receptor binding density in the substantia nigra of these mice
[157]. While this indicates CBD can have ameliorative effects
on schizophrenia-relevant behaviours, it also shows that the
effects of CBD can depend on the model used, the age targeted
(e.g. adolescence vs adulthood) and the dose used.
Cannabinoids: ∆9-Tetrahydrocannabinol
Several models of genetic risk for schizophrenia are more sen-
sitive to behavioural and neural effects of THC. The dominant
negative Disc1 (DN-Disc1) mutant mouse is more susceptible
to the effects of adolescent THC treatment than WT controls
[158]. Chronic THC in adolescence increases anxiolytic be-
haviour and impairs short-term memory in DN-Disc1 mutant
mice, where these effects are not apparent in WT controls [158].
The cognitive impairment induced by THC in DN-Disc1 mice
may be linked to hippocampal CB1 receptor and BDNF levels,
as chronic THC selectively increases hippocampal CB1 receptor
and BDNF protein levels in WT mice but not in DN-Disc1 mice
[158]. Interestingly, overexpression of hippocampal BDNF in
DN-Disc1 mice prevents THC-induced cognitive impairment in
these mice, suggesting that BDNF upregulationmay be a home-
ostatic response designed to maintain proper cognitive func-
tion following exogenous insult [158].
In the Nrg1 TM HET model of genetic risk for schizophrenia,
Nrg1 TM HET males are more sensitive to the locomotor sup-
pressing and PPI enhancing effects of acute THC than are THC–
treated WT controls [159]. Female Nrg1 TM HET mice do not
exhibit this elevated sensitivity to THC in terms of locomotion
and PPI, and are even less susceptible than WTs to the supress-
ing effects of THC on some social behaviours [160]. The Nrg1
gene mutation assessed also impacts on susceptibility to THC,
as male mice from a different Nrg1 mutant model, i.e. Nrg1 III
tg mice do not exhibit altered THC-induced locomotion, social
behaviour or prepulse inhibition, compared to THC-treated WT
controls [161].
In adolescence, the Nrg1 TM HET mutation protects against
inhibiting effects of chronic THC on investigative social be-
haviours in male mice [162]. However, adolescent Nrg1 TM
HET mice continue to demonstrate locomotor suppression af-
ter 2 days washout from THC where WTs do not, suggesting
increased susceptibility to locomotor, but not social effects of
THC in adolescent Nrg1 TM mutants [162].
There are complex effects of chronic adolescent THC treat-
ment on receptor expression across the brain in Nrg1 TM HET
mice. Chronic adolescent THC increases CB1 receptor binding
in the substantia nigra in Nrg1 but not WTmice [162]. Consider-
ing the role of CB1 receptors in controlling dopamine release in
the basal ganglia direct pathway, this elevation in CB1 recep-
tor binding may reflect continued suppression of locomotion
following chronic THC in adolescent Nrg1 mutant mice [162].
In addition, the elevation in NMDA receptor binding in the hip-
pocampus, auditory cortex and cingulate cortex in THC-treated
adolescent Nrg1 TM HET but not WT mice may also contribute
to the continued locomotor suppression in Nrg1 mutants, as
NMDA receptor antagonism induces hyperlocomotion, and in-
creased NMDA receptor binding may reflect reduced locomo-
tion ([162] see also [163]). Finally, adolescent THC treatment
increases 5-HT2A receptor binding in the agranular insular cor-
tex in Nrg1 mutants, whereas in WTs, THC treatment reduces
5-HT2A binding in the agranular insular cortex, ventral pal-
lidum and cingulate cortex, and increases 5-HT2A binding in
the caudate-putamen [162]. In patients with schizophrenia, re-
duced 5-HT2AR density is observed post-mortem in prefrontal
and other cortical regions [164, 165], and may relate to social
withdrawal and social anxiety observed in patients. The ele-
vation of 5-HT2A receptor binding in Nrg1 mutants may re-
flect the protective effect of the Nrg1 genotype on the social
behaviour-suppressing effects of THC [162].
Using a proteomics approach, Spencer and colleagues [163]
demonstrated that adolescent Nrg1 TM mutants chronically
treated with THC show an altered profile of proteins which
affect synapse formation and dendritic spine dynamics [163].
Chronic adolescent THC in Nrg1 mutants induces changes in
several proteins involved in intracellular trafficking and stabi-
lization of NMDA receptors at the synapse (e.g. FLOT1, APOA1,
GPSM2) [163]. Interestingly, THC treatment caused proteomic
changes in WT mice suggestive of greater oxidative stress and
neurodegeneration than in Nrg1 mutant mice, again suggest-
ing a degree of protection against some effects of THC in Nrg1
TM HET mice [163]. These findings may help to explain the
altered behavioural responses of Nrg1 TM HET mice to cannabi-
noid treatment.
Clinical data indicates a complex relationship between
cannabis use and schizophrenia susceptibility between the
sexes [166–169]. It is possible risk genes modulate this re-
lationship, e.g. BDNF Val66Met genotype when coupled with
cannabis abuse modulates risk for psychosis onset in females,
but not males [167]. The preclinical data presented above
suggests complex interactions between cannabinoid treatment,
schizophrenia genetic susceptibility and sex, where cannabi-
noids can both protect against and worsen schizophrenia-like
behaviour. Further investigation into sex differences in these
cannabis-gene interactions is warranted.
3.2 Lesion models
Psychostimulants: amphetamine
In NVHL rats, acute amphetamine-induced locomotion is en-
hanced compared to sham controls [72, 77, 85]. The effects
of NVHL on amphetamine-induced locomotion may be age-
dependent, as rats in early adolescence (i.e. PND 35) do not
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exhibit altered acute amphetamine-induced locomotion com-
pared to controls, where NVHL rats in late adolescence/young
adulthood (PND 56) do [85]. This indicate an age * drug in-
teraction in NVHL rats, potentially reflecting late adolescent
developmental changes in the mesolimbic pathway, relevant
to the development of schizophrenia at this age.
Nicotine
NVHL rats exhibit deficits in learning and memory in the radial
arm maze [72, 74, 170]. Unlike some genetic models (e.g. G72
transgenic mice, reeler mice, Type III Nrg1 HET mice, detailed
above), chronic nicotine treatment in adolescence or adulthood
does not reverse cognitive impairment in the radial arm maze
in NVHL rats [72, 74, 170]. Chronic adolescent or adult nico-
tine treatment also does not differentially affect nACh recep-
tor binding in mPFC or ventral striatum in NVHL rats com-
pared to sham controls [170]. These studies suggest limited
effects of nicotine on learning and memory, as well as nACh
receptor binding in NVHL rats. The effects of nicotine on other
schizophrenia-relevant domains e.g. hyperlocomotion, social
behaviour, sensorimotor gating are yet to be examined.
3.3 Non-lesion neurodevelopmental models
Psychostimulants: amphetamine
Offspring of maternal LPS-treated rats are more sensitive to
amphetamine in early adulthood, displaying a reduced break-
point for a food reinforcer under amphetamine treatment, and
greater amphetamine-induced locomotion than controls [171].
However, these effects depend on the gestational day (G12 vs
G16) at which LPS is administered, suggesting age-specific ef-
fects of LPS on brain development and subsequent drug reward
susceptibility [171]. Embryonic midbrain dopaminergic neu-
rons are reduced 48 hr after LPS treatment at E16 but this re-
covers by adolescence, while midbrain dopaminergic neurons
are unaffected by LPS treatment at E12 [171]. This suggests
altered dopaminergic function following maternal LPS treat-
ment, which is protocol dependent and shows a degree of re-
covery with time. Considering the recovery of dopaminergic
midbrain neurons following LPS treatment, it is possible sensi-
tivity to amphetamine in LPS rats is mediated by dopaminergic
neurons in a different brain region e.g. forebrain regions such
as the dorsal and ventral striatum.
Nicotine
Cognitive deficits in rats prenatally treated with LPS are ame-
liorated by chronic nicotine self-administration, compared to
LPS rats which self-administer saline [100]. This may indi-
cate a restoration of deficits in nicotinergic α7 and α4β2 re-
ceptor subtype function in LPS treated rats; however, this has
not been assessed experimentally [100]. The effects of acute
or chronic nicotine in neurodevelopmental models (e.g. MAM,
Poly I:C, LBN) have not yet been assessed. However, consid-
ering interactions between the immune system and nicotine
[172, 173], this is an interesting area of future research.
Cannabinoids: CBD, WIN, fatty acid amide hydrolase inhibitors
Osborne and colleagues examined the effects of CBD in a rat
Poly I:C model of maternal infection, which exhibit cognitive
deficits and social interaction impairment [174]. In males,
chronic CBD treatment in early adulthood rescued deficits in
short term working memory in the novel object recognition
test and rewarded t-maze, as well as social interaction deficits
in Poly I:C rats, with no effects of CBD in non-Poly I:C treated
rats [174]. Chronic CBD treatment in early adulthood attenu-
ated Poly I:C-induced deficits in CB1 receptor binding in the
PFC as well as GAD67 binding in the hippocampus [175]. CBD
also increased protein levels of the interneuron marker parval-
bumin in the hippocampus, irrespective of maternal infection,
but did not affect NMDA or GABA-A receptor binding or pro-
tein levels of fatty acid amide hydrolase (FAAH), the enzyme
which degrades anandamide, in the PFC or hippocampus. Over-
all, these findings suggest that in male rats, CBD may reverse
schizophrenia-relevant negative and cognitive behaviours by
restoring cannabinoid/GABAergic signalling deficits.
Similarly, in female Poly I:C rats, chronic CBD in early
adulthood attenuates recognition memory and social interac-
tion deficits, and reverses the Poly I:C induced reduction in
NMDA receptor binding in the PFC [176]. Poly I:C also in-
creases GAD67 and parvalbumin interneuron protein levels in
the hippocampus [176]. Interestingly, CBD administration con-
trol rats (i.e. no Poly I:C treatment) reduces social interaction,
as well as cannabinoid CB1 receptor and NMDA receptor binding
in the PFC, suggesting that CBD administration to healthy rats
may have negative consequences on social behaviour and brain
maturation in adulthood [176]. Together, this supports the an-
tipsychotic potential of CBD for the treatment of cognitive and
negative symptoms in schizophrenia but not healthy controls
(review: [151]), and suggests CBD could be acting by reversing
PFC CB1 and NMDA receptor dysfunction and increasing GABA
receptor function in the hippocampus, in a sex-specific man-
ner.
In another model of maternal infection, the MAM model,
chronic adolescent treatment with the CB1 receptor agonist
WIN prevents amphetamine-induced hyperlocomotion, but
does not reverse deficits in a set-shifting task in MAM treated
rats [177]. Interestingly, the effect of WIN on amphetamine-
induced locomotion in MAM rats occurs in the absence of
changes to dopaminergic neuron firing in the VTA [177], al-
though cell activity in other brain regions relevant to locomotor
sensitization (e.g. NAcc) were not assessed in this study. These
findings are surprising as CB1 receptor agonists often exacer-
bate schizophrenia symptoms [178]. The authors suggest that
pubertal exposure to WIN may have changed the expression
of components of the endocannabinoid system in brain struc-
tures related to motivation and motor control, thus limiting
amphetamine-induced hyperlocomotion in MAM rats [177].
In a novel rodent model of schizophrenia susceptibility, the
F2 methylazoxymethanol acetate (F2 MAM) rat, where only a
proportion ( 40%) of rats display a schizophrenia-relevant phe-
notype (i.e. hyperdopaminergic phenotype characterized by in-
creased dopamine neuron activity in the VTA), subchronic ado-
lescent WIN treatment increases the proportion of F2 MAM rats
with a schizophrenia-like phenotype (i.e. hyperdopaminergia)
in early adulthood (i.e. from 36% to 71%), with no correspond-
ing increase in schizophrenia-like phenotypes in WT controls
[179]. Adolescent WIN treatment also increases sensitivity to
acute amphetamine locomotor activity in early adulthood in F2
MAM rats, compared to WT controls [179]. Similarly, increas-
ing endogenous cannabinoid signalling via the FAAH inhibitor
URB597 also increases the proportion of F2 MAM rats with a
schizophrenia-like phenotype in early adulthood (i.e. from
40% to 80%), but unlike WIN treatment, has no effect on am-
phetamine sensitivity [179]. This data mirrors clinical observa-
tions of increased risk for developing schizophrenia following
cannabis abuse in individuals with genetic risk for the disor-
der [180–182], and will facilitate further investigation of the
molecular and genetic mechanisms driving this susceptibility.
3.4 Pharmacological models
Psychostimulants: amphetamine
In a rat model of dopamine supersensitivity (i.e. withdrawal
from chronic haloperidol), amphetamine treatment increases
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the pursuit of food-based reward cues more vigorously in
dopamine supersensitive rats than control rats [183–185]. This
effect does not appear mediated by NAcc function, as intra-
NAcc amphetamine injections or NAcc inhibition via GABA re-
ceptor agonists does not alter pursuit of food-based cues [185].
Baseline food-seeking, however, is unaltered by dopamine
supersensitivity [183]. Amphetamine-induced locomotion as
well as c-fos mRNA in the caudate putamen is also elevated fol-
lowing chronic haloperidol, compared to vehicle-treated con-
trols [184]. While further research needs to be conducted in
this field, these results suggest altered reward could be present
in schizophrenia-relevant pharmacological models of altered
dopamine function.
Nicotine
Information processing, in particular 40 Hz steady-state audi-
tory evoked responses, is deficient in patients with schizophre-
nia [186], and assessment of auditory evoked responses in ro-
dents can be used to model this in the laboratory. Acute MK-
801 impairs auditory-evoked neural responses in anaesthetised
rats [187], and MK-801 also exacerbates psychotic symptoms
in patients with schizophrenia [188]. Interestingly, MK-801
induced impairment in auditory-evoked responses is amelio-
rated by acute nicotine administration [187]. Similarly, acute
MK-801-induced memory impairments in mice are improved
by acute nicotine administration [189], while chronic nico-
tine reverses heightened impulsivity in a mouse chronic PCP
model [190]. Finally, systemic and intra-orbitofrontal cor-
tex administration of nicotine or the nAChR agonist ABT-418
dose-dependently ameliorates chronic ketamine-induced im-
pairments in a multisensory integration task, and this effect
is blocked by GABA-A receptor antagonism [191]. These ef-
fects appear dependent on parvalbumin interneurons in the or-
bitofrontal cortex, as silencing parvalbumin interneurons im-
pairs multisensory integration task performance, and this is
reversed by ABT-418 administration [191]. Collectively, this
suggests acute and chronic nicotine can improve cognitive im-
pairment in an MK-801 schizophrenia rodent model, an effect
which may depend on parvalbumin interneuron function in the
PFC.
Cannabinoids: THC, WIN, FAAH inhibitors
PCP treatment, either neonatally or in adulthood, increases be-
havioural and brain responses to cannabinoids. A single neona-
tal PCP administration at G7 increases vulnerability to chronic
adolescent THC-induced deficits in memory performance and
sensorimotor gating [192]. Neonatal PCP also induces hyper-
locomotion in adult mice which are chronically treated with
THC (n.b. mice were tested for locomotor activity after at least
27 days of THC treatment, reducing the sedative effects of THC
[192]). These behavioural effects are associated with reduced
NMDA NR1 receptor protein in the cortex, reflecting a reduction
in glutamatergic signalling which is hypothesised to contribute
to schizophrenia pathophysiology [192].
When rats are treated subchronically in adulthood with PCP,
this increases mPFC firing rates in response to the FAAH in-
hibitor URB597, suggesting increased susceptibility to elevated
levels of endocannabinoids in PCP-treated rats compared to
vehicle-treated controls [193]. Conversely, PCP-treated ani-
mals are unaffected by THC, where THC treatment decreases
mPFC firing rates in saline treated animals [193]. Subchronic
PCP treatment does not modulate firing rates in response to
URB597 or THC in the ventral hippocampus, suggesting an
mPFC-specific effect [193]. Considering neural oscillations are
disrupted in schizophrenia, and cannabinoids can acutely de-
crease the power of neural oscillations [194], these findings
can start to shed light on how cannabinoids affect mPFC neu-
ral firing in schizophrenia.
Interestingly, cannabinoids may have protective effects
when administered prior to PCP. In rats which either self-
administer or are treated chronically with the CB1 receptor ago-
nist WIN, the sensitized locomotor response to a PCP challenge
is decreased in WIN-treated animals, compared to vehicle con-
trols [195]. WIN self-administration also increases exploratory
behaviour (i.e. rearing) and reduces anxiety-like behaviour
in an open field arena in response to acute PCP administra-
tion [195]. Interestingly, PCP-induced social withdrawal and
reduced anandamide levels in the PFC and amygdala can be
reversed by elevating endogenous cannabinoids via the FAAH
inhibitor URB597, or by increasing cannabinoid signalling via
the cannabinoid agonist CP55,940 [196, 197]. This suggests
PCP-induced social withdrawal and sensitized locomotor ac-
tivity may result from deficient endocannabinoid transmission
[196].
In a rat model selectively bred following social isolation
housing and ketamine treatment in adolescence, WIN-induced
G-protein activation is reduced in the cerebellum, cortex and
in subcortical regions [198]. CB1 receptor binding is also re-
duced in the cerebellum, cortex and subcortical regions in
this rat model of schizophrenia, compared to controls [198].
These reductions in cannabinoid receptor binding and func-
tion correspond with similar endocannabinoid system changes
and elevated susceptibility to cannabinoids in patients with
schizophrenia (e.g. [199–201]).
Together, these results suggest cannabinoids generally
worsen positive-like and cognitive behaviours, and cause al-
tered receptor binding (e.g. cannabinoid, glutamatergic) and
mPFC firing in pharmacological models of schizophrenia. This
reflects clinical data, which demonstrates cannabis use can
worsen symptoms in patients with schizophrenia, and in first
episode patients, recent cannabis use is associated with de-
creased grey matter volume in the posterior cingulate cortex
(review: [202]). Interestingly, in rodent models, the timing of
cannabinoid administration can modulate this effect; cannabi-
noid administration prior to PCP treatment appears protective
against schizophrenia-relevant behaviours.
3.5 Interim Summary
In Section 3, we summarised how abused drugs can exacer-
bate or alleviate schizophrenia-relevant behaviours in several
rodent models of schizophrenia. Interestingly, there are some
fairly consistent findings across models and drug classes. Nico-
tine, for example, often ameliorates schizophrenia-relevant
behaviours, as observed in most genetic models, one neurode-
velopmental model and one pharmacological model. Cannabi-
noids have bidirectional effects on schizophrenia-relevant be-
haviours, with CB1 agonists (e.g. THC, WIN) mostly wors-
ening these behaviours in genetic, neurodevelopmental and
pharmacological models (although there are some exceptions),
and CBD ameliorating schizophrenia-like behaviours in ge-
netic and neurodevelopmental models. There is limited data
available on the effects of psychostimulants on schizophrenia-
relevant behaviour; however, lesion and pharmacological mod-
els show elevated sensitivity to psychostimulants, which can
be age-dependent. The effects of nicotine, cannabinoids and
psychostimulants mirrors what is observed in clinical litera-
ture, e.g. nicotine improves attention and processing speed
in individuals with schizophrenia [203, 204], cannabis wors-
ens schizophrenia symptoms and clinical prognosis [205], CBD
has antipsychotic-like effects [206], and there is recent evi-
dence of increased susceptibility to effects of amphetamine on
sensorimotor gating in schizophrenia [207]. Importantly, this
provides predictive validity to these models, and facilitates the
use of these models to better understand brain changes associ-
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ated with drug susceptibility. The research reviewed above in-
dicates that chronic nicotine has a range of effects on the brain
in schizophrenia models, including reducing striatal D2 recep-
tor mediated LTD in Snap-25 KO mice, increasing GAD67 and
reelin mRNA in the cortex, hippocampus, striatum and cerebel-
lum of reeler mice, and differential theta burst stimulated LTP
in cortico-BLA synapses in Type III Nrg1HETmice. Chronic THC
alters CB1 receptor binding in the substantia nigra and CB1 pro-
tein levels in the hippocampus in genetic models (i.e. Nrg1 TM
HET and DN-Disc1). Chronic THC also alters protein binding of
NMDA and 5-HT2A receptors in the cortex and hippocampus of
Nrg1 TM HET mice, potentially reflecting genotype-specific ef-
fects of THC on locomotion and social behaviour. Endocannabi-
noid signalling (e.g. firing rates following FAAH inhibitor
administration, WIN-induced g-protein activation or anan-
damide levels) are also altered in the PFC and amygdala and
cerebellum in pharmacological (e.g. PCP) and two-hit mod-
els (e.g. ketamine and social isolation), suggesting changes
to endocannabinoid function potentially reminiscent of endo-
cannabinoid system changes in patients with schizophrenia
[199–201]. The antipsychotic-like effects of CBD may be me-
diated by reversing changes to PFC CB1 and NMDA receptor
dysfunction and increasing GABA receptor binding in the hip-
pocampus and PFC in schizophrenia models. Finally, while
there has been limited examination of how psychostimulants
affect neural function in schizophrenia models, elevated c-fos
mRNA expression in the caudate-putamen following chronic
haloperidol suggests sensitized dopaminergic function in re-
ward regions and may also contribute to drug-seeking suscep-
tibility.
4. Conclusions
There has been a vast addition to the preclinical literature in-
vestigating schizophrenia and drug abuse comorbidity since
2013, and it is becoming increasingly apparent that drug ad-
diction behaviours and susceptibility to effects of abused drugs
exist in many schizophrenia models. This is an exciting de-
velopment, and suggests a burgeoning new field which could
lead to breakthroughs in our understanding of comorbidity be-
tween schizophrenia and addiction. Importantly, in this review
we have highlighted how often addiction-like behaviour is ob-
served in different models of schizophrenia, particularly in ge-
netic and neurodevelopmental models. We also found signifi-
cant support for each hypothesis to explain drug susceptibility
in schizophrenia: neurodevelopmental and some genetic mod-
els support the primary addiction hypothesis; genetic, neurode-
velopmental and pharmacological models support the two-hit
hypothesis, particularly for cannabinoids and nicotine, while
genetic models often support the self-medication hypothesis
for nicotine. Interestingly, this review found that the suscep-
tibility of schizophrenia models to drug abuse appears to of-
ten implicate altered dopaminergic function (e.g. increased
dopamine D2 receptor expression and dopamine metabolism),
particularly in reward relevant regions such as the PFC and
NAcc. This is relevant as changes in dopamine receptor expres-
sion are observed in drug abuse patients [5], and alterations to
the dopaminergic system is consistent finding in schizophre-
nia, suggesting that schizophrenia susceptibility may alter
drug reward pathways to elevate risk for drug abuse. It is inter-
esting to note that cognitive impairment in some models (e.g.
NVHL model) correlates with drug abuse susceptibility; inves-
tigating this in other models would be of considerable interest.
Furthermore, when examining susceptibility of schizophre-
nia models to abused drugs, there are effects on several neuro-
transmitter systems highly relevant to schizophrenia and ad-
diction, primarily in mesocorticolimbic structures. Nicotine
treatment has ameliorative effects on schizophrenia relevant
behaviour in several models (e.g. genetic and pharmacolog-
ical models, but not the NVHL model), and this may be de-
pendent on actions at α7 nicotinergic receptors. Several mod-
els are more susceptible to the effects of cannabinoids such
as THC and CBD on schizophrenia-relevant behaviours, and
this is accompanied by complex changes in cannabinoid, gluta-
matergic, serotonergic and GABAergic receptor systems. Con-
sidering changes to these systems have all been reported in
schizophrenia [208, 208–211], these findings not only vali-
date the models used, but indicate how changes in these sys-
tems are relevant to both schizophrenia and drug susceptibil-
ity. Changes to specific receptor systems and subunits indi-
cates which targets are specifically affected by drug exposure
in schizophrenia, increasing our understanding of interactions
between these disorders and potentially providing targets for
future pharmacotherapies specifically designed to treat addic-
tion in schizophrenia.
However, there are still several gaps in the literature which
need to be addressed. To date, there has been very limited
investigation into the molecular correlates of susceptibility to
abused drugs. Also, most research has examined the response
of schizophreniamodels to effects of nicotine and cannabinoids
on schizophrenia-like behaviours, yet behavioural and neural
responses to other drugs of abuse (e.g. alcohol, psychostimu-
lants, opioids), remains mostly unexplored. Other critical ar-
eas of future research include investigating addiction-like be-
haviour for non-psychostimulant drugs in genetic and phar-
macological models of schizophrenia, as well as investigating
potential sex-specific effects in terms of addiction-relevant be-
haviour. Poly-drug use has rarely been examined (but see a
recent example: [75]), yet considering that poly-drug use is
common in schizophrenia [212, 213], this is another research
area with incredible potential. Addressing these gaps in the lit-
erature will thoroughly advance our understanding of the com-
plex relationship between schizophrenia and drug abuse, and
eventually help to better treat addiction in schizophrenia.
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